Answers are grounded in this paper and cite their sources.
Open-label trial demonstrates neratinib's 10% radiographic response in patients with nf2-related schwannomatosis, suggesting potential for further evaluation.
BACKGROUND NF2-related schwannomatosis (NF2-SWN) predisposes affected individuals to vestibular schwannomas (VS), non-vestibular schwannomas (NVS), meningiomas, and ependymomas. Previous trials of erbB1/EGFR and erbB2/HER2 inhibitors have shown some efficacy against VS. Neratinib is a potent irreversible pan-erbB inhibitor. We report the results of the interim analysis of the neratinib treatment arm of INTUITT-NF2. METHODS We conducted a multicenter, phase II, open-label basket trial of neratinib for subjects (≥12 years old) with NF2-SWN and progressive tumors (baskets: VS, NVS, meningioma, or ependymoma). Twenty participants were accrued (≥2 participants per basket). Tumor response was evaluated by MRI every 3 months in year 1 and every 6 months thereafter. Radiographic response was defined as ≥20% decrease in tumor volume below baseline. Primary outcome was the radiographic response rate (RR). Pre- and post-treatment growth rates were determined using pre-baseline and study MRI scans. RESULTS Twenty subjects (median age=27 years; range, 12-45 years) were treated with neratinib. Target tumors included 10 VS, 3 NVS, 5 meningiomas, and 2 ependymomas; non-target tumors included 20 VS, 14 NVS, 13 meningiomas, and 2 ependymomas. Radiographic RR for target and all tumors was 10% and 13%, respectively. By tumor basket, radiographic RR for all tumors was 0% for VS, 35% for non-VS, 17% for meningioma, and 0% for ependymomas. Average annualized tumor growth rates decreased for VS, NVS, meningioma, and ependymoma during neratinib treatment. There were no serious adverse events and five grade 3 treatment-related adverse events (all diarrhea). Three patients held or delayed dose due to grade 2/3 toxicity (diarrhea, rash, malaise), and two discontinued treatment during cycle 1 (diarrhea, malaise). CONCLUSIONS Neratinib treatment showed modest efficacy in treatment of tumors associated with NF2-SWN. Based on this interim analysis, the team will explore whether an additional 20 participants will be enrolled in the two most promising tumor baskets.
No takes yet. Share an insight, caveat, or question.
Plotkin et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: